Abcam, ab135924, Anti-SLC22A6 antibody

Size: 100µg
Rabbit Polyclonal SLC22A6 antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human, Mouse samples. Cited in 14 publications. Immunogen corresponding to Synthetic Peptide within Human SLC22A6.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Human,
Applications:IHC-P, WB, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human SLC22A6. The exact immunogen used to generate this antibody is proprietary information.Q4U2R8

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 50% Glycerol (glycerin, glycerine), 0.88% Sodium chloride, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The SLC22A6 protein also known as organic anion transporter 1 (OAT1) functions mechanically as a transporter that facilitates the movement of organic anions across cell membranes. The protein has a molecular mass of about 56 kDa. Expression of SLC22A6 occurs in various tissues with significant levels in the kidneys where it is found in the basolateral membrane of the renal proximal tubules. This expression profile highlights its key role in renal function particularly in the excretion and detoxification processes.
Biological function summary
SLC22A6 plays a role in the renal secretion of endogenous substances and drugs. It is part of the organic anion transporter family and participates in the elimination of molecules such as prostaglandins urate and multiple pharmaceutical agents. By functioning in concert with other transporter proteins SLC22A6 influences the pharmacokinetics of drugs and the clearance of metabolic waste products. Its activity ensures the proper balance of organic anions contributing to homeostasis.
Pathways
SLC22A6 integrates into the metabolic and excretory pathways in the kidney. It is part of the metabolic detoxification process capturing drugs and metabolites for renal excretion. The transporter works in a network that includes proteins such as SLC22A8 and urate-anion exchanger (URAT1) ensuring efficient substance clearance. In drug metabolism SLC22A6 interaction determines drug disposition with implications for drug efficacy and toxicity.
Researchers have identified SLC22A6 as significantly involved in the pathogenesis of chronic kidney disease (CKD) and hypertension. Variation or malfunction in this transporter can affect the renal excretion of toxic metabolites and drugs contributing to CKD progression. Additionally altered function of SLC22A6 influences blood pressure regulation linking it to hypertension. These associations highlight the importance of SLC22A6 as a therapeutic target in treating renal and cardiovascular disorders.